Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Association Between Semaglutide Use and NAION
TAKE-HOME MESSAGE
- An analysis of a large global database was conducted to examine the incidence of non-arteritic anterior ischemic optic neuropathy (NAION) in three groups of Caucasian patients taking semaglutide versus non–glucagon-like peptide 1 receptor agonist (GLP-1RA) medications for lowering glucose or weight loss: patients with type 2 diabetes mellitus (T2DM) who were not obese, patients who were obese without a T2DM diagnosis, and patients with both T2DM and obesity. In all three groups, the use of semaglutide was not associated with an increased risk of NAION compared with the use of non–GLP-1RA medications.
- These findings do not show an increased risk of NAION in patients taking semaglutide for T2DM and/or obesity. Further studies are indicated.
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersOBJECTIVE
To investigate whether semaglutide increases the risk of non-arteritic anterior ischemic optic neuropathy (NAION) in the general population.
DESIGN
This retrospective cohort study utilized a de-identified global electronic medical records database. The enrollment period was extended from January 2017 to August 2023, with observations concluding in August 2024.
PARTICIPANTS
This study included individuals with type 2 diabetes mellitus (T2DM) or obesity. They were further categorized into T2DM-only, obesity-only, and T2DM with obesity groups to assess the differences among these subgroups. The effects of semaglutide were compared with those of glucose-lowering or weight loss medications other than glucagon-like peptide receptor agonists.
METHODS
Patient data were obtained from 160 healthcare organizations across 21 countries. Outcomes were evaluated at one, two, and three years of follow-up. A 1:1 propensity score matching was performed to balance age, sex, body mass index, hemoglobin A1C, medications, and underlying comorbidities. Cox regression models were used to compute hazard ratios (HR) and 95% confidence intervals (CI).
MAIN OUTCOME MEASURES
The occurrence of NAION.
RESULTS
The final analysis included 37,245 participants with T2DM-only, 33,537 participants with obesity-only, and 64,989 participants with both T2DM and obesity. The results indicated that the administration of semaglutide was not associated with the development of NAION in the T2DM-only group (1 year follow-up: HR, 2.32; 95% CI, 0.60-8.97; 2 years: HR, 2.31; 95% CI, 0.86-6.17; 3 years: HR, 1.51; 95% CI, 0.71-3.25), the obesity-only group (1 year follow-up: HR, 0.25; 95% CI, 0.03-2.28; 2 years: HR, 0.44; 95% CI, 0.09-2.21; 3 years: HR, 0.44; 95% CI, 0.09-2.21), and the T2DM with obesity group (1 year follow-up: HR, 0.81; 95% CI, 0.42-1.57; 2 years: HR, 1.2; 95% CI, 0.74-1.94; 3 years: HR, 1.19; 95% CI, 0.78-1.82).
CONCLUSIONS
The findings suggest that semaglutide may not be associated with an increased risk of NAION in the general population. Therefore, avoidance of semaglutide based solely on concerns regarding the risk of NAION may not be warranted, as its potential benefits for blood glucose control and cardiovascular health likely outweigh its potential risks.
Additional Info
Association between Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Real-World Study
Ophthalmology 2024 Nov 02;[EPub Ahead of Print], CC Chou, SY Pan, YJ Sheen, JF Lin, CH Lin, HJ Lin, IJ Wang, CH WengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.